Ok, maybe I should have reworded that, as what and how management or third-party organisations are thinking re: Long CoVID is anyone's idea.
The question should have been, how applicable are the autoimmune therapies, IMP761 IMP731 in the treatment of long CoVID should an over-active immune system be responsible for the syndrome / symptoms. Maybe this is a question for a different thread?
Tuts / Hodgie, thoughts?
Ann: COVID-19 phase 2 investigator initiated trial commences, page-35
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.005(1.59%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.0¢ | 30.5¢ | $922.9K | 2.963M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 149460 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |